Cefpodoxime Proxetil Dispersible Tablets

Cefpodoxime proxetil is an oral broad-spectrum third-generation cephalosporin. After entering the body, it is hydrolyzed into cefpodoxime by nonspecific esterase to exert antibacterial effects. It is effective against both Gram-positive and Gram-negative bacteria. The mechanism of action of this product is to achieve bactericidal effects by inhibiting the biosynthesis of microbial cell walls. This product is stable to szlig;-lactamase, so many szlig;-lactamase-producing microorganisms that are resistant to penicillin and cephalosporins are still sensitive to this product. This product is ineffective against some ultra-extended-spectrum β-lactamases. In vitro and clinical infection studies have confirmed that this product is active against most of the following microorganisms: 1. Aerobic Gram-negative microorganisms: Staphylococcus aureus (including penicillinase-producing strains), Streptococcus pyogenes. 2. Aerobic Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis, and Neisseria gonorrhoeae (including penicillinase-producing strains). This product is active against most of the following microorganisms in vitro, but its clinical significance is still unclear. 1. Aerobic Gram-positive microorganisms - Streptococcus agalactiae, Streptococcus (groups C, F, G). However, this product is ineffective against enterococci. 2. Aerobic Gram-negative microorganisms - Citrobacter heteromorphicus, Klebsiella oxytoca, Proteus vulgaris, Providencia rettgeri, Haemophilus parainfluenzae. However, this product is inactive against most Pseudomonas and Enterobacter. 3. Anaerobic Gram-positive microorganisms - Peptostreptococcus spp. Toxicological studies Genetic toxicity: In vivo and in vitro studies (including Ames test, chromosome aberration test, unscheduled DNA synthesis test, mitotic recombination, gene recovery, forward gene mutation test and in vivo micronucleus test) did not find that this product has genetic toxicity. Reproductive toxicity: When rats were orally given this product at a dose of about 100 mg/kg/day (based on body surface area, twice the human dose), no effect of this product on animal fertility and reproductive function was observed. No teratogenicity and embryotoxicity. When the rabbit dose reaches 30mg/kg/day (1-2 times the human dose based on body surface area), no teratogenicity and embryotoxicity are observed. There is no sufficient and rigorous research data on pregnant women. Since animal experiments cannot fully predict human conditions, pregnant women can only use it when it is really necessary. There is no experience of using this product during delivery, so it should only be used when it is really necessary. Cefpodoxime proxetil may be secreted in human breast milk. Because this product has potential serious reactions to breastfeeding infants, the pros and cons to the mother and baby should be weighed before deciding whether to interrupt breastfeeding or discontinue the drug. Carcinogenicity: There is no long-term animal carcinogenicity research data on this product.

Cefpodoxime Proxetil

This product is a film-coated tablet, which appears off-white or slightly yellow after removing the coating.

Cefpodoxime Proxetil Dispersible Tablets; Anti-infection, anti-inflammatory treatment, antibiotic drugs.

Oral administration after meals. For adults, take 0.1-0.2g each time, twice a day, depending on the type of disease and condition. Generally, for upper respiratory tract infection and simple urinary tract infection, take 0.1g each time, twice a day; for severe cases, the dosage can be increased to 0.2g, twice a day, for a course of 5-7 days. For lower respiratory tract infection, complicated urinary tract infection, skin and soft tissue infection, ear, nose and throat infection, take 0.2g each time, twice a day, for a course of 7-14 days.

1. Serious adverse reactions of this product: 1) Shock: It may occasionally cause symptoms of shock. You should pay attention to observation. If you experience discomfort, abnormal sensation in the mouth, wheezing, dizziness, urge to defecate, tinnitus, sweating, etc., you should stop taking the drug. 2) Mucocutaneous eye syndrome, toxic epidermal necrolysis: Mucocutaneous eye syndrome (Stevens-Johnson syndrome) and toxic epidermal necrolysis (Lyell syndrome) may occur occasionally. You should pay attention to observation. If any abnormality occurs, you should stop taking the drug and deal with it appropriately. 3) Pseudomembranous colitis: Severe colitis such as pseudomembranous colitis accompanied by bloody stools may occur occasionally. If abdominal pain or frequent diarrhea occurs, you should stop taking the drug immediately and deal with it appropriately. 2. Serious adverse reactions that may be caused by similar drugs: 1) Pancytopenia, agranulocytosis, hemolytic anemia; other cephalexin antibiotics have caused

Patients with a history of allergy to this product or cephem antibiotics are contraindicated.

Precautions for children: The safety of the drug for use in children has not been established (little experience in use). Precautions for pregnancy and lactation: The safety of the drug for use during pregnancy has not been established, so pregnant women or women who may become pregnant should only use the drug when the benefits of treatment outweigh the risks. Precautions for the elderly: The elderly should pay attention to the following content and dosage and dosing interval, observe the patient's condition, and administer the drug with caution. (1) The elderly often have reduced physiological functions and are prone to side effects. (2) The elderly may have a tendency to bleed due to vitamin K deficiency.

1. Antacids (sodium bicarbonate or sodium hydroxide) and H2 receptor antagonists combined with this product can reduce the absorption and blood concentration of this product. Anticholinergics can reduce peak concentrations, but do not affect the degree of absorption (AUC). 2. Similar to other szlig;-lactam antibiotics, taking probenecid at the same time will inhibit the excretion of this product from the kidney, resulting in increased AUC and Cmax. 3. Although the toxicity of this product when used alone is less, close attention should be paid to its simultaneous use with other drugs known to be nephrotoxic.

Keep in a dark place, sealed and stored. Validity period: 12 months

0.1g (based on C15H17N5O6S2)

December

Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd.

• Founded in:

  2001-02-28

• Address:

  No. 9, Hantai North Road, Huai'an City, Jiangsu Province

• Tax NO.:

  91320800134784998M

• Registered Funds:

  180 million yuan

• Website:

  Log in to view

• Email:

  Log in to view